B cell biomarkers of rituximab responses in systemic lupus erythematosus.

@article{Vital2011BCB,
  title={B cell biomarkers of rituximab responses in systemic lupus erythematosus.},
  author={E M Vital and Shouvik Dass and M H Buch and Karen T Henshaw and Colin Thomas Pease and Michael F Martin and Fr{\'e}d{\'e}rique Ponchel and Andrew C Rawstron and P T J Emery},
  journal={Arthritis and rheumatism},
  year={2011},
  volume={63 10},
  pages={3038-47}
}
OBJECTIVE Rituximab appears to be effective in many studies of systemic lupus erythematosus (SLE), with variable initial clinical response and time to relapse. However, results of a randomized controlled trial of rituximab were negative. This study was undertaken to evaluate the effectiveness of rituximab in SLE, using highly sensitive flow cytometry (HSFC), which can define B cell numbers 50-100 times lower than conventional techniques and predicts responses in rheumatoid arthritis. METHODS… CONTINUE READING